Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Metabolic dysfunction-associated steatotic liver disease and its link to cancer
Metabolic-dysfunction associated steatotic liver disease (MASLD), formerly known as
nonalcoholic fatty liver disease (NAFLD), is a growing global health concern with significant …
nonalcoholic fatty liver disease (NAFLD), is a growing global health concern with significant …
[HTML][HTML] Glucagon-like peptide-1 receptor agonists and risk of gastrointestinal cancers: A systematic review and meta-analysis of randomized controlled trials
Background Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used for
glucose lowering and weight-loss. However, their association with gastrointestinal cancer …
glucose lowering and weight-loss. However, their association with gastrointestinal cancer …
Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: target trial emulation using real-world data
W Wang, ND Volkow, NA Berger, PB Davis… - Annals of Internal …, 2024 - acpjournals.org
Background: Reports of reduced desire to smoke in patients treated with semaglutide, a
glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus …
glucagon-like peptide receptor agonist (GLP-1RA) medication for type 2 diabetes mellitus …
Impact of GLP‐1RA on the Risk of Adverse Liver Outcomes Among Patients With Alcohol‐Associated Liver Disease and Type 2 Diabetes
ABSTRACT Background and Aims We sought to characterise the impact of GLP‐1RA on
adverse liver outcomes (ALO) among patients with alcohol‐associated liver disease (ALD) …
adverse liver outcomes (ALO) among patients with alcohol‐associated liver disease (ALD) …
Associations of semaglutide with first‐time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real‐world data in …
INTRODUCTION Emerging preclinical evidence suggests that semaglutide, a glucagon‐like
peptide receptor agonist (GLP‐1RA) for type 2 diabetes mellitus (T2DM) and obesity …
peptide receptor agonist (GLP‐1RA) for type 2 diabetes mellitus (T2DM) and obesity …
[HTML][HTML] Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma
Background/Objectives: Hepatocellular carcinoma (HCC) is a leading cause of cancer-
related mortality worldwide, primarily develo** in the context of chronic liver disease …
related mortality worldwide, primarily develo** in the context of chronic liver disease …
Global Trend of MASH-associated Liver Cancer: A Systematic Analysis From the Global Burden of Disease 2021
Background & Aims Metabolic dysfunction-associated steatotic liver disease (MASLD) and
metabolic dysfunction-associated steatohepatitis (MASH) are the leading causes of liver …
metabolic dysfunction-associated steatohepatitis (MASH) are the leading causes of liver …
An updated overview on hepatocellular carcinoma in patients with Metabolic dysfunction-Associated Steatotic Liver Disease: Trends, pathophysiology and risk-based …
Hepatocellular carcinoma (HCC) is a relevant complication occurring in individuals with
advanced Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). Recent …
advanced Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). Recent …
Glucose‐lowering drugs and liver‐related outcomes among individuals with type 2 diabetes: A systematic review of longitudinal population‐based studies
Aims While randomized controlled trials data on the long‐term effect of glucose‐lowering
drugs (GLDs) on liver‐related outcomes are lacking, population‐based studies have …
drugs (GLDs) on liver‐related outcomes are lacking, population‐based studies have …
Influence of glucagon‐like peptide‐1 receptor agonists on hepatic events in type 2 diabetes: a systematic review and meta‐analysis
PRC Passos, VOC Filho, MM Noronha… - Journal of …, 2025 - Wiley Online Library
Abstract Background and Aim Type 2 diabetes mellitus (T2DM) is intrinsically linked to
various etiologies of liver disease, with 69% of patients having concomitant metabolic …
various etiologies of liver disease, with 69% of patients having concomitant metabolic …